文献速递前列腺癌

临床局限性前列腺癌初始治疗后生化复发者 salvage 雄激素剥夺治疗与死亡率的关系

Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
PubMed 文献 · J Urol · 2016-12-19

该回顾性队列纳入3个管理式医疗组织1995至2009年新诊断局限性前列腺癌、初始根治性前列腺切除术或放疗后出现生化复发的全部5,804例男性患者。总体上 salvage 雄激素剥夺治疗与全因或前列腺癌特异性死亡率无关;但在前列腺特异性抗原倍增时间小于9个月的患者中,该治疗与全因和前列腺癌特异性死亡率降低存在统计学显著关联。

要点

  • 总体 salvage 雄激素剥夺治疗与全因及前列腺癌特异性死亡率无关。
  • 前列腺切除术后 PSA 倍增时间小于9个月者,salvage 雄激素剥夺治疗与全因死亡率降低相关(HR 0.35)。
  • 放疗后 PSA 倍增时间小于9个月者,salvage 雄激素剥夺治疗与全因死亡率降低相关(HR 0.62)。

核心结论

  • 在大多数临床局限性前列腺癌初始根治性前列腺切除术或放疗后生化复发的男性中,salvage 雄激素剥夺治疗与全因或病因特异性死亡率无关联。
  • 疾病快速进展的男性可能从 salvage 雄激素剥夺治疗中获得临床获益。

研究设计与样本

  • 来自3个管理式医疗组织的回顾性队列,纳入1995至2009年新诊断局限性前列腺癌、初始根治性前列腺切除术或放疗后出现前列腺特异性抗原升高(生化复发)的全部5,804例男性。
  • 主要结局为全因死亡率和前列腺癌特异性死亡率,采用 Cox 比例风险模型将 salvage 雄激素剥夺治疗作为时间依赖预测因子估计死亡率。

主要发现

  • 总体 salvage 雄激素剥夺治疗与前列腺切除术后队列的全因死亡率(HR 0.97,95%CI 0.70-1.35)或前列腺癌特异性死亡率(HR 1.18,95%CI 0.68-2.07)无关联。
  • 总体 salvage 雄激素剥夺治疗与放疗后队列的全因死亡率(HR 0.84,95%CI 0.70-1.01)或前列腺癌特异性死亡率(HR 1.06,95%CI 0.80-1.40)无关联。
  • 前列腺特异性抗原升高后倍增时间小于9个月的男性中,salvage 雄激素剥夺治疗与前列腺切除术后队列全因死亡率降低(HR 0.35,95%CI 0.20-0.63)和前列腺癌特异性死亡率降低(HR 0.43,95%CI 0.21-0.91)存在统计学显著关联。
  • 前列腺特异性抗原升高后倍增时间小于9个月的男性中,salvage 雄激素剥夺治疗与放疗后队列全因死亡率降低(HR 0.62,95%CI 0.48-0.80)和前列腺癌特异性死亡率降低(HR 0.65,95%CI 0.47-0.90)存在统计学显著关联。

临床怎么用

  • 原文结论认为,大多数临床局限性前列腺癌初始根治性前列腺切除术或放疗后生化复发的男性中,salvage 雄激素剥夺治疗与全因或病因特异性死亡率无关联。
  • 原文结论认为,疾病快速进展的男性可能从 salvage 雄激素剥夺治疗中获得临床获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Androgen deprivation therapy is often used as salvage treatment in men with rising prostate specific antigen after initial radical prostatectomy or radiotherapy for clinically localized prostate cancer. Given the lack of evidence from general practice, we examined the association of salvage androgen deprivation therapy with mortality in an observational cohort study. MATERIALS AND METHODS: From 3 managed care organizations we assembled a retrospective cohort of all 5,804 men with newly diagnosed localized prostate cancer from 1995 to 2009 who had a prostate specific antigen increase (biochemical recurrence) after primary radical prostatectomy or radiotherapy. The main outcomes were all-cause and prostate cancer specific mortality. We used Cox proportional hazards models to estimate mortality with salvage androgen deprivation therapy as a time dependent predictor. RESULTS: Overall salvage androgen deprivation therapy was not associated with all-cause or prostate cancer specific mortality in the prostatectomy cohort (HR 0.97, 95% CI 0.70-1.35 or HR 1.18, 95% CI 0.68-2.07) or in the radiotherapy cohort (HR 0.84, 95% CI 0.70-1.01 or HR 1.06, 95% CI 0.80-1.40, respectively). Among men with prostate specific antigen doubling time less than 9 months after the prostate specific antigen rise, salvage androgen deprivation therapy was statistically significantly associated with a decreased risk of all-cause and prostate cancer specific mortality in the prostatectomy cohort (HR 0.35, 95% CI 0.20-0.63 and HR 0.43, 95% CI 0.21-0.91) and in the radiotherapy cohort (HR 0.62, 95% CI 0.48-0.80 and HR 0.65, 95% CI 0.47-0.90, respectively). CONCLUSIONS: We found no association of salvage androgen deprivation therapy with all-cause or cause specific mortality in most men with biochemical recurrence after primary radical prostatectomy or radiotherapy for clinically localized prostate cancer. Men with quickly progressed disease may derive a clinical benefit from salvage androgen deprivation therapy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Fu AZ, Tsai HT, Haque R, et al. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol. 2016. PMID: 28007467. doi:10.1016/j.juro.2016.12.086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。